Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth

Burnett G, Kennedy EP (1954) The enzymatic phosphorylation of proteins. J Biol Chem 211:969–980

Tuazon PT, Traugh JA (1991) Casein kinase I and II—multipotential serine protein kinases: structure, function, and regulation. Adv Second Messenger Phosphoprotein Res 23:123–164

Pinna LA (1990) Casein kinase 2: an ‘eminence grise’ in cellular regulation? Biochim Biophys Acta 1054:267–284

Buchou T, Vernet M, Blond O et al (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23:908–915

Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, Seldin DC (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28:131–139

Poole A, Poore T, Bandhakavi S, McCann RO, Hanna DE, Glover CV (2005) A global view of CK2 function and regulation. Mol Cell Biochem 274:163–170

Seldin DC, Lou DY, Toselli P, Landesman-Bollag E, Dominguez I (2008) Gene targeting of CK2 catalytic subunits. Mol Cell Biochem 316:141–147

Solyakov L, Cain K, Tracey BM et al (2004) Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem 279:43403–43410

Wang H, Yu S, Davis AT, Ahmed K (2003) Cell cycle dependent regulation of protein kinase CK2 signaling to the nuclear matrix. J Cell Biochem 88:812–822

Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K (2001) A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 276:5992–5999

Cavin LG, Romieu-Mourez R, Panta GR et al (2003) Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 38:1540–1551

Kato T Jr, Delhase M, Hoffmann A, Karin M (2003) CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 12:829–839

Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K (2008) Protein kinase CK2—a key suppressor of apoptosis. Adv Enzyme Regul 48:179–187

Canton DA, Litchfield DW (2006) The shape of things to come: an emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal 18:267–275

Gu L, Husain-Ponnampalam R, Hoffmann-Benning S, Henry RW (2007) The protein kinase CK2 phosphorylates SNAP190 to negatively regulate SNAPC DNA binding and human U6 transcription by RNA polymerase III. J Biol Chem 282:27887–27896

Guo C, Davis AT, Yu S, Tawfic S, Ahmed K (1999) Role of protein kinase CK2 in phosphorylation nucleosomal proteins in relation to transcriptional activity. Mol Cell Biochem 191:135–142

Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62:6770–6778

Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349–368

Filhol O, Cochet C (2009) Cellular functions of Protein kinase CK2: a dynamic affair. Cell Mol Life Sci. doi: 10.1007/s00018-009-9151-1

Jakobi R, Traugh JA (1992) Characterization of the phosphotransferase domain of casein kinase II by site-directed mutagenesis and expression in Escherichia coli. J Biol Chem 267:23894–23902

Grankowski N, Boldyreff B, Issinger OG (1991) Isolation and characterization of recombinant human casein kinase II subunits alpha and beta from bacteria. Eur J Biochem 198:25–30

Bodenbach L, Fauss J, Robitzki A et al (1994) Recombinant human casein kinase II. A study with the complete set of subunits (alpha, alpha′ and beta), site-directed autophosphorylation mutants and a bicistronically expressed holoenzyme. Eur J Biochem 220:263–273

Filhol O, Cochet C, Wedegaertner P, Gill GN, Chambaz EM (1991) Coexpression of both alpha and beta subunits is required for assembly of regulated casein kinase II. Biochemistry 30:11133–11140

Bibby AC, Litchfield DW (2005) The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci 1:67–79

Bjorling-Poulsen M, Siehler S, Wiesmuller L, Meek D, Niefind K, Issinger OG (2005) The ‘regulatory’ beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation. Oncogene 24:6194–6200

Vilk G, Derksen DR, Litchfield DW (2001) Inducible expression of the regulatory protein kinase CK2beta subunit: incorporation into complexes with catalytic CK2 subunits and re-examination of the effects of CK2beta on cell proliferation. J Cell Biochem 84:84–99

Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I (2005) CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 274:63–67

Guerra B, Issinger OG (2008) Protein kinase CK2 in human diseases. Curr Med Chem 15:1870–1886

Sarno S, Pinna LA (2008) Protein kinase CK2 as a druggable target. Mol Biosyst 4:889–894

Munstermann U, Fritz G, Seitz G, Lu YP, Schneider HR, Issinger OG (1990) Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J Biochem 189:251–257

Prowald K, Fischer H, Issinger OG (1984) Enhanced casein kinase II activity in human tumour cell cultures. FEBS Lett 176:479–483

Siemer S, Ornskov D, Guerra B, Boldyreff B, Issinger OG (1999) Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin. Int J Biochem Cell Biol 31:661–670

Channavajhala P, Seldin DC (2002) Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21:5280–5288

Unger GM, Davis AT, Slaton JW, Ahmed K (2004) Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 4:77–84

Li D, Dobrowolska G, Aicher LD et al (1999) Expression of the casein kinase 2 subunits in Chinese hamster ovary and 3T3 L1 cells provides information on the role of the enzyme in cell proliferation and the cell cycle. J Biol Chem 274:32988–32996

Landesman-Bollag E, Song DH, Romieu-Mourez R et al (2001) Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 227:153–165

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2:712–721

Faust RA, Tawfic S, Davis AT, Bubash LA, Ahmed K (2000) Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 22:341–346

Seeber S, Issinger OG, Holm T, Kristensen LP, Guerra B (2005) Validation of protein kinase CK2 as oncological target. Apoptosis 10:875–885

Yamane K, Kinsella TJ (2005) Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine. Clin Cancer Res 11:2355–2363

Izeradjene K, Douglas L, Delaney A, Houghton JA (2005) Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24:2050–2058

Yamane K, Kinsella TJ (2005) CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer Res 65:4362–4367

Sandholt IS, Olsen BB, Guerra B, Issinger OG (2009) Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 20:238–248

Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA (2004) 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321:1040–1044

Meggio F, Pagano MA, Moro S et al (2004) Inhibition of protein kinase CK2 by condensed polyphenolic derivatives, An in vitro and in vivo study. Biochemistry 43:12931–12936

Nie Z, Perretta C, Erickson P et al (2008) Structure-based design and synthesis of novel macrocyclic pyrazolo[1, 5-a] [1, 3, 5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 18:619–623

Pagano MA, Bain J, Kazimierczuk Z et al (2008) The selectivity of inhibitors of protein kinase CK2. An update. Biochem J 415:353–365

Vilk G, Saulnier RB, St Pierre R, Litchfield DW (1999) Inducible expression of protein kinase CK2 in mammalian cells. Evidence for functional specialization of CK2 isoforms. J Biol Chem 274:14406–14414

Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T (2005) Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280:35195–35202

Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760–763

Borowski P, Deinert J, Schalinski S et al (2003) Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem 270:1645–1653

Sarno S, de Moliner E, Ruzzene M et al (2003) Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5, 6-dihydroindolo-(1, 2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J 374:639–646

Zien P, Abramczyk O, Domanska K, Bretner M, Szyszka R (2003) TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications. Biochem Biophys Res Commun 312:623–628

Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1–15

Raaf J, Klopffleisch K, Issinger OG, Niefind K (2008) The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin. J Mol Biol 377:1–8

Sarno S, Salvi M, Battistutta R, Zanotti G, Pinna LA (2005) Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754:263–270

Cherry M, Williams DH (2004) Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem 11:663–673

Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K (2005) Targeting CK2 for cancer therapy. Anticancer Drugs 16:1037–1043

Bretner M, Najda-Bernatowicz A, Lebska M, Muszynska G, Kilanowicz A, Sapota A (2008) New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole. Mol Cell Biochem 316:87–89

Pagano MA, Andrzejewska M, Ruzzene M et al (2004) Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 47:6239–6247

Pagano MA, Cesaro L, Meggio F, Pinna LA (2006) Protein kinase CK2: a newcomer in the ‘druggable kinome’. Biochem Soc Trans 34:1303–1306

Scaglioni PP, Yung TM, Cai LF et al (2006) A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269–283

Perera Y, Farina HG, Hernandez I et al (2008) Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer 122:57–62

Lebrin F, Chambaz EM, Bianchini L (2001) A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha. Oncogene 20:2010–2022

Pagano MA, Poletto G, Di Maira G et al (2007) Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 8:129–139

Miyata Y, Nishida E (2008) Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol Cell Biochem 316:127–134